IL12-engineered human PSMA-CAR T cells for the treatment of advanced prostate cancer - PubMed
5 hours ago
- #CAR T cell therapy
- #prostate cancer
- #IL12 engineering
- IL12-engineered human PSMA-CAR T cells are developed for treating advanced prostate cancer.
- The therapy targets prostate-specific membrane antigen (PSMA) using a human scFv-based CAR for improved safety and efficacy.
- A membrane-bound IL-12 (mbIL12) molecule is introduced to enhance T cell expansion, IFNy production, and anti-tumor activity.
- The engineered CAR T cells show potent anti-tumor responses in bone-metastatic prostate cancer models.
- The therapy aims to provide a safer and more effective treatment for PSMA+ prostate cancer.